The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > June 2, 2025
Daily News
June 2, 2025
- Scemblix’s 1st Line Nod Will Take CML Therapy to New Stage: Professor
June 2, 2025
- New Skipper of PMDA’s Review Center Wears Multiple Hats to Push Fight against Drug Loss
June 2, 2025
- Shionogi’s OIC Med Naldemedine Accepted for Review in China
June 2, 2025
- Astellas Nabs Rights to China Firm’s CLDN18.2 ADC
June 2, 2025
- LDP Group Urges Ministers to Keep Coverage of Pain Relief Patches
June 2, 2025
- PMDA Reviewing Safety Risks of Thiamazole, Desmopressin
June 2, 2025
- Daiichi/Merck Pull HER3-DXd Filing for NSCLC in US
June 2, 2025
- Novo Pairs Up with Sumitomo on Ozempic Promotion in Japan
June 2, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…